In pharmaceutical manufacturing, active pharmaceutical ingredients (APIs) often get the spotlight, but excipients play a vital role in drug formulation. Whether you are developing a tablet, capsule, injectable, or inhalable product, excipients influence everything from stability and solubility to bioavailability and dosing accuracy.
One common question we hear is:
Do excipients need FDA approval?
The short answer is not exactly. But they are regulated, and using the right excipients in the right way is essential for getting your drug product approved.
What Is an Excipient?
An excipient is any inactive substance in a drug product that is not the active ingredient. While they are often called inactive, excipients serve critical functions such as:
- Acting as binders, fillers, lubricants, or disintegrants
- Improving taste or mouthfeel
- Controlling the release rate of the API
- Stabilizing the formulation for storage or transport
The choice and quality of excipients can significantly affect a drug’s effectiveness, shelf life, and patient experience.
Does the FDA Approve Excipients Directly?
No, the FDA does not individually approve excipients in the same way it approves drug products.
Instead, excipients are evaluated as part of the overall New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The FDA looks at:
- The identity and quality of each excipient
- Whether it has been used before in approved drug products
- Its intended function and quantity in the formulation
- Safety data, especially if it is a novel or high-risk excipient
If the excipient is already listed in the FDA Inactive Ingredient Database (IID), that is often considered a positive indicator of prior regulatory acceptance.
Are Novel Excipients a Risk?
Yes. Introducing a new or novel excipient that is not listed in the IID may trigger additional regulatory scrutiny. Sponsors may need to submit toxicology data, and the FDA may request more extensive studies to assess its safety profile.
This makes standardization and consistency across batches essential, especially in how excipients are processed and micronized.
Why Particle Size of Excipients Matters
At Sturtevant Inc., we help pharmaceutical manufacturers control particle size and shape of both APIs and excipients, ensuring:
- Even distribution of excipients across tablets or capsules
- Improved content uniformity in low-dose drugs
- Faster or more controlled dissolution rates, depending on the application
- Enhanced blend flowability and compressibility during production
Our Micronizer Jet Mill allows companies to reduce excipients like lactose, mannitol, or microcrystalline cellulose down to narrow particle size distributions without generating heat or causing contamination. This level of control helps ensure consistency across clinical trials and commercial-scale production, which supports regulatory approval processes.
How to Minimize Regulatory Risk When Working with Excipients
- Use compendial-grade excipients whenever possible (USP-NF)
- Reference the FDA Inactive Ingredient Database to confirm prior use
- Rely on trusted vendors who provide certificates of analysis and documentation
- Ensure uniform particle size and material handling to support consistent performance
- Use equipment like the Micronizer that minimizes contamination and enables repeatability
Final Thoughts
While excipients do not require independent FDA approval, their function, quality, and handling are crucial to getting your drug product approved. By choosing the right excipients and processing them to exacting standards, you reduce regulatory risk and improve product performance.
Want to learn how micronizing your excipients can enhance your formulation?
Fill out the form below to request a free consultation and experience the Sturtevant advantage firsthand.